DOCSLIB.ORG

Sino Biological Inc. 北京义翘神州生物技术有限公司 GENE|PROTEIN|ANTIBODY|ELISA

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sino Biological Inc. 北京义翘神州生物技术有限公司 GENE|PROTEIN|ANTIBODY|ELISA Sino Biological Inc. 北京义翘神州生物技术有限公司 GENE|PROTEIN|ANTIBODY|ELISA 北京义翘神州生物技术有限公司（Sino Biological Inc.）成立于 2007 年，是北京市高新技术企业，是科技部认定的“现代服务业创 新发展示范企业”。重点从事重组蛋白、抗体、细胞因子、cDNA 、ELISA 试剂盒、转染试剂等产品的研发和生产。产品应用于免疫学、 肿瘤、神经生物学、干细胞、病毒等相关领域的生命科学研究以及药物研发。同时，义翘神州也致力于生物技术药物如单克隆抗体、重 组蛋白药物、病毒疫苗、快速诊断试剂等的研究开发服务。 义翘神州拥有全球领先的重组蛋白药物和单克隆抗体生产工艺和技术平台。每年新增重组蛋白、抗体近 2000 种，已成为全球十强药 企在重组蛋白和单克隆抗体研究开发领域的首选技术服务供应商，产品均产自义翘神州高度集中化的生产实验室，质量控制严格，绝无 代工产品。 义翘神州产品已经销往全球 87 个国家和地区，得到了世界范围内 11500 家用户的认可。义翘神州生产的重组蛋白 80% 以上为真核 表达，更接近天然蛋白的性质，因此具有更好的生物活性；单抗产品检测灵敏度比国际主流试剂供应商产品高 10-100 倍。相比国外品牌， 义翘神州保证科研、企业用户以更低的费用和更快的配送服务获得更高品质的科研试剂。 目录 CONTENTS 产品优势 .......................................................................................................... 2 产品列表 .......................................................................................................... 4 药物靶点 .......................................................................................................... 14 药物靶点文献例证 ......................................................................................... 16 02 产品优势 义翘 CD 分子 生物活性高涵盖热点药物靶点现货库存，满足多种功能应用蛋白纯度高多组织验证高亲和力，高灵敏度兔单抗 & 鼠单抗可供选择 24h 内发货 Human CD32a binding to IgG Human CD16a (158V) binding to IgG CD331(FGFR1)Fms-like tyrosine kinase 10374-H08H 5 10389-H08H1 10616-H03H 90 4 4 80 3 3 70 2 2 OD450nm-B 60 OD450nm-B 1 1 50 0 0 40 1E-3 0.01 0.1 1 10 1E-3 0.01 0.1 1 10 1E-3 0.01 0.11 1 10 100 1000 humanhuman lgG1 Con.Con.(μg/ml) (ug/ml) humanhuman lgG1 lgG1 Con. Con.(μg/ml) (ug/ml) FGFR1-Fch Con.(ng/ml) 在线订购：cn.sinobiological.com 产品信息或有更新，请以网站为准。 马上订购 电话：400-890-9989 邮箱：[email protected] 传真：010-51029969 产品优势 03 多组织验证 同靶点：鼠单抗 & 兔单抗 其他 IHC 引用范例 E-cadherin-pAb-1ug- E-cadherin-pAb-1ug- CEACAM1-5ug-intestine, CEACAM1-15ug-liver, mCD34-0.2ug-heart B7-1-1ug-lung IHC-P, Human Liver IHC-P, colon-carcinoma Rabbit mAb Mouse mAb Cat.No.50589-T24-50 Cat.No.10698-T24-100 Cat.No.10204-T58-100 Cat.No.10204-T58-100 Cat.No.50571-R030-50 Cat.No.10822-MM02-50 c-KIT-3ug-IHC-P, skin c-KIT-3ug-IHC-P, B7-H1-5ug-placenta, B7-H1-30ug-placenta, VEGFR2-1ug-kidney ANXA6-0.2ug-pancreas Cat.No.11996-R351-100 breast-cancer Rabbit mAb Mouse mAb Cat.No.10012-T24-100 Cat.No.100742-T40-100 Cat.No.11996-R351-100 Cat.No.10084-R015-50 Cat.No.10084-MB55-100 IP 引用范例 target-cell:LAMP1-MCF7 target-cell:GCSFR-MCF7 target-cell:E-CAD-P-MCF7 target-cell:CD340-SKBR3 target-cell:CD321-A431 target-cell:CD9-Hela Cat.No.11215-MM07 Cat.No.10218-MM03 Cat.No.10204-MM08 Cat.No.10004-R511 Cat.No.10198-MM04 Cat.No.11029-MM01 在线订购：cn.sinobiological.com 产品信息或有更新，请以网站为准。 马上订购 电话：400-890-9989 邮箱：[email protected] 传真：010-51029969 产品列表 (CD1-30) 04Name Alias Human protein Human antibody application Mouse protein Mouse antibody application CD1b T6 11831-H02H WB CD1d R3G1 11009-H08H 50188-M08H CD2 T11, LFA-2, SRBC-R, Erythrocyte receptor, LFA-3R 10982-H08H WB, ELISA, IHC-P, FCM 50537-M08H WB, ELISA, IHC-P CD3gd T3D, OKT3 10981-H08H WB, ELISA, IHC-P, IP 50390-M02H CD3e T3E, TCRE 10977-H08H WB, ELISA, IHC-P, FCM, IP CD4 T4 10400-H03H WB, ELISA, IHC-P, FCM 50134-M08H ELISA, IHC-P CD5 T1, Tp67, LEU1 11027-H08H WB, ELISA, IHC-P, FCM, IP 50403-M08H WB, ELISA, IHC-P, FCM, ICC/IF CD6 T12, OX52, TP120 50711-M02H ELISA, FCM, ICC/IF CD7 LEU 9, GP40, TP41 11028-H08H WB, ELISA, IHC-P, IP 50393-M08H ELISA CD8a T8, Leu-2, MAL 10980-H08H ELISA, IHC-P, FCM 50389-M08H ELISA, FCM, ICC/IF CD8b CD8B1 11031-H02H ELISA, IHC-P CD9 p24, MRP-1, 5H9 antigen, MIC3, TSPAN29, GIG2 11029-H08H FCM, ICC/IF CD10 CALLA, NEP, gp100, Neprilysin, SFE, MME, EPN 10805-H01H ELISA, FCM 50218-M07H CD11c p150, 95, CR4, integrin αX, LFA-1A, ITGAL CT017-H2508H CD13 Aminopeptidase N, APN, ANPEP,PEPN 10051-H08H WB, ELISA, IHC-P, IP 50001-M08H ELISA, IHC-P CD14 LPS-R 10073-H01H ELISA, IHC-P, FCM 50023-M03H ELISA, FCM, ICC/IF CD16a FcγRIIIA, FCGR3A, FCG3, FCGR3, IGFR3 10389-H08H ELISA, IHC-P 50326-M08H CD16b FcγRIIIB, FCGR3B, FCG3, FCGR3, IGFR3 11046-H08H ELISA, IHC-P CD18 Integrin β2, ITGB2, MFI7 CT015-H2508H CD19 B4, Leu-12 11880-H08H ELISA, IHC-P, IP 50510-M08H CD20 B1, Bp35, MS4A1 11007-H07H2 WB, ELISA, IHC-P, FCM CD21 C3DR, CR2, EBV-R 10811-H08H WB, ELISA, IHC-P, IP CD22 BL-CAM, Siglec-2, Leu-14 11958-H08H ELISA 51177-M08H CD23 FcεRII, BLAST-2, FCER2, CLEC4J 10261-H07H WB, ELISA, IHC-P 50695-M07H ELISA, FCM, ICC/IF CD24 BA-1, Nectadrin 11030-H02H 50717-M02H CD25 Tac, p55, IL2RA 10165-H02H ELISA 50292-M08H ELISA, FCM CD26 DPP IV, DPP4, ADABP, ADCP2 10688-H01H 50718-M01H CD27 T14, TNFRSF 7, CD27L receptor 10039-H03H ELISA, IHC-P, FCM 50110-M03H ELISA, IHC-P, FCM, ICC/IF CD28 Tp44, T44 11524-H02H ELISA 50103-M03H WB, ELISA CD29 Integrin β1, ITGB1, FNRB CT014-H2508H CD30 Ki-1, TNFRSF8 10777-H03H WB, ELISA, IHC-P, FCM, IP *IHC-P: 免疫组化（石蜡切片）; WB: 蛋白免疫印迹 ; FCM: 流式细胞实验 ; ELISA: 酶联免疫吸附试验 ; ICC/IF: 免疫细胞化学 / 免疫荧光实验 ; IP: 免疫共沉淀实验 在线订购：cn.sinobiological.com 产品信息或有更新，请以网站为准。 马上订购 电话：400-890-9989 邮箱：[email protected] 传真：010-51029969 产品列表 (CD31-59) Name Alias Human protein Human antibody application Mouse protein Mouse antibody05 application CD31 PECAM-1 10148-H02H WB, ELISA, IHC-P, FCM, IP 50408-M08H ELISA CD32a FcγRII, FCGR2A 10374-H08H WB, ELISA 50030-M08H CD32b FcγRII, FCGR2B 10259-H08H WB, ELISA, IHC-P, FCM 50712-M02H CD33 p67, Siglec-3 12238-H08H ELISA 50589-M08H ELISA CD34 10103-H02H ELISA ELISA, IHC-P, FCM CD35 CR1, C3b/C4b receptor IHC-P CD36 GPIV, GP3B, GP4 10752-H08H WB, ELISA, IHC-P, FCM 50422-M03H CD37 TSPAN26 WB 50719-M01H CD38 T10, ADP ribosyl cyclase 1 10818-H08H WB, ELISA, IHC-P, IP 50191-M08H ELISA, IHC-P, FCM CD39 NTPDase 1, ENTPD1 10909-H08B 50398-M08B ELISA CD40 TNFRSF5 10774-H03H WB, ELISA, FCM, ICC/IF 50324-M03H CD42c GPIbb 10742-H08H CD43 Leukosialin, sialophorin, SPN 50735-M02H CD44 H-CAM, Pgp-1, Epican, HUTCH-I, LHR, ECMR-III 12211-H08H WB, ELISA, IHC-P, FCM, ICC/IF CD45 LCA, T200, B220, PTPRC 10086-H02H ELISA, FCM 50713-MCCB CD46 MCP, TLX 12239-H08H WB, ELISA, IHC-P, FCM, ICC/IF, IP CD47 IAP, MER6 12283-H02H ELISA CD48 Blast-1, BCM1 10797-H08H WB, ELISA, FCM, IP 50415-M08H ELISA, FCM, ICC/IF CD49b VLA-2, TGA2 WB CD49c VLA-3, TGA3 IHC-P CD49e VLA-5, TGA5 CT014-H2508H CD49f VLA-6, TGA6 CT013-H2508H IHC-P CD50 ICAM-3 10333-H03H WB, ELISA, IHC-P, FCM, IP CD51 Vitronectin receptor, ITGAV, MSK8 IHC-P CD52 CAMPATH-1, HE5 15105-H02H 50721-M02H CD53 Tetraspanin-25, MOX44 50722-M07H CD54 ICAM-1 10346-H03H WB, ELISA, IHC-P, FCM, ICC/IF, IP 50440-M03H ELISA, IHC-P, FCM CD55 DAF 10101-H02H WB, ELISA, IHC-P, FCM, ICC/IF, IP 50468-M08H ELISA, FCM, ICC/IF CD56 NCAM1 10673-H08H WB, ELISA, IP CD58 LFA-3 12409-H08H ELISA CD59 Protectin, MAC- inhibitor 12474-H08H WB, ELISA, IP 50724-M08H *IHC-P: 免疫组化（石蜡切片）; WB: 蛋白免疫印迹 ; FCM: 流式细胞实验 ; ELISA: 酶联免疫吸附试验 ; ICC/IF: 免疫细胞化学 / 免疫荧光实验 ; IP: 免疫共沉淀实验 在线订购：cn.sinobiological.com 产品信息或有更新，请以网站为准。 马上订购 电话：400-890-9989 邮箱：[email protected] 传真：010-51029969 产品列表 (CD61-85) 06Name Alias Human protein Human antibody application Mouse protein Mouse antibody application CD61 GPIIIa, ITGB3, GP3A IHC-P CD62E E-selectin, ELAM-1, SELE 10335-H03H WB, ELISA, FCM 50736-M08H ELISA CD62L L-selectin, LECAM-1, SELL 11838-H08H ELISA 50045-M03H ELISA, IHC-P, FCM CD62P P-selectin, PADGEM, SELP, LECAM3 13025-H08H ELISA 50737-M08H ELISA CD63 LIMP, LAMP-3, MLA1 11271-H08H ELISA, IHC-P, FCM 50557-MNCH CD64 FcγRI, FCGR1A 10256-H08H 50086-M08H CD66a BGP-1, NCA-160, CEACAM1 10822-H03H WB, ELISA, IHC-P, FCM 50571-M08H ELISA, IHC-P, FCM, ICC/IF CD66b CD67, CGM6, CEACAM8 11729-H08H ELISA, FCM CD66c NCA, CEACAM6 10823-H08H ELISA, FCM CD66d CGM1, CEACAM3 11933-H08H ELISA, FCM CD66e CEA, CEACAM5 11077-H03H ELISA, IHC-P, FCM CD66f PSG, Sp-1, PSBG1 15378-H08H CD68 Macrosialin, gp110, KP1 11192-H03H ELISA, IHC-P CD69 AIM, CLEC2C, EA1 11150-H08H WB, ELISA, IP 50731-M08H CD70 Ki-24, CD27L 10780-H01H 51129-M04H CD71 T9, TFRC 11020-H07H WB, ELISA, IHC-P, FCM, ICC/IF, IP 50741-M07H ELISA CD72 Lyb-2, Ly-19, Ly-32 50732-M08H CD73 5’-nucleotidase, NT5E 10904-H08H WB, ELISA, IP 50231-M08H ELISA CD74 LN2, Ii, DHLAG 11091-H07H WB, ELISA, IHC-P, FCM, IP CD75 ST6GAL1, Sialyltransferase 1 11590-H07H WB, ELISA, IHC-P, IP 50740-M07H CD77 Gb3, Pk blood group, BLA WB CD79a MB1, IGA 13208-H08H WB, IHC-P 50734-M02H CD79b B29, IGB 50754-M08H CD80 B7, B7-1, BB1 10698-H03H WB, ELISA, IHC-P, FCM 50446-M08H ELISA CD81 TAPA-1, Tetraspanin-28 14244-HNCH 50743-M04H CD82 R2, KAI1, Tetraspanin-27 12275-H08H WB, ELISA, IHC-P,IP CD83 HB15 11763-H08H WB, ELISA, IHC-P 50694-M08H ELISA CDw84 SLAM5 10100-H08H WB, ELISA 50757-M08H ELISA CD85a LILRB3, ILT5, LIR3 11978-H08H ELISA, FCM 50760-M08H ELISA, ICC/IF CD85c LILRB5, LIR8 IHC-P CD85d LILRB2, ILT4, LIR2, MIR10 14132-H08H *IHC-P: 免疫组化（石蜡切片）; WB: 蛋白免疫印迹 ; FCM: 流式细胞实验 ; ELISA: 酶联免疫吸附试验 ; ICC/IF: 免疫细胞化学 / 免疫荧光实验 ; IP: 免疫共沉淀实验 在线订购：cn.sinobiological.com 产品信息或有更新，请以网站为准。 马上订购 电话：400-890-9989 邮箱：[email protected] 传真：010-51029969 产品列表 (CD85-119) Name Alias Human protein Human antibody application Mouse protein Mouse antibody application07 CD85e LILRA3, ILT6, LIR4 16014-H08H ELISA CD85f LILRA5, ILT11, LIR9 16059-H08H CD85i LILRA1, LIR6 WB, IP CD85j LILRB1, ILT2, LIR1 16014-H08H ELISA, FCM CD86 B70, B7-2, CD28LG2 10699-H03H ELISA, FCM 50068-M03H WB, ELISA, IP CD87 UPA-R, PLAUR, MO3 10925-H08H ELISA, FCM 50160-M03H ELISA CD89 FcαR 10414-H08H ELISA, FCM CD90 Thy-1 WB 50461-M08H ELISA, IHC-P CD91 LRP1,A2MR,APOER 11665-HCCH CD93 C1qR, C1QR1, MXRA4 12589-H02H CD95 Apo-1, FASLG, APTL, TNFSF6 10217-H02H ELISA, FCM 50027-M08H ELISA, FCM CD96 TACTILE 11202-H08H ELISA 50758-M08H WB, ELISA, IHC-P CD97 11280-H08H WB, ELISA, FCM, ICC/IF, IP CD98 4F2hc, SLC3A2, MDU1 12206-H07H WB, ELISA, IHC-P, IP 50813-M07H WB, ELISA, IHC-P CD99 MIC2, E2 50520-M02H
Load more

Recommended publications
  • North Fork of the St. Lucie River Floodplain Vegetation Technical Report
    NORTH FORK ST. LUCIE RIVER FLOODPLAIN VEGETATION TECHNICAL REPORT WR-2015-005 Coastal Ecosystem Section Applied Sciences Bureau Water Resources Division South Florida Water Management District Final Report July 2015 i Resources Division North Fork of the St. Lucie River Floodplain Vegetation Technical Report ACKNOWLEDGEMENTS This document is the result of a cooperative effort between the Coastal Ecosystems Section of South Florida Water Management District (SFWMD) and the Florida Department of Environmental Protection (FDEP), Florida Park Service (FPS) at the Savannas Preserve State Park in Jensen Beach, Florida and the Indian River Lagoon Aquatic Preserve Office in Fort Pierce, Florida. The principle author of this document was as follows: Marion Hedgepeth SFWMD The following staff contributed to the completion of this report: Cecilia Conrad SFWMD (retired) Jason Godin SFWMD Detong Sun SFWMD Yongshan Wan SFWMD We would like to acknowledge the contributions of Christine Lockhart of Habitat Specialist Inc. with regards to the pre-vegetation plant survey, reference collection established for this project, and for her assistance with plant identifications. We are especially grateful to Christopher Vandello of the Savannas Preserve State Park and Laura Herren and Brian Sharpe of the FDEP Indian River Lagoon Aquatic Preserves Office for their assistance in establishing the vegetation transects and conducting the field studies. And, we would like to recognize other field assistance from Mayra Ashton, Barbara Welch, and Caroline Hanes of SFWMD. Also, we would like to thank Kin Chuirazzi for performing a technical review of the document. ii North Fork of the St. Lucie River Floodplain Vegetation Technical Report TABLE OF CONTENTS Acknowledgements ..........................................................................................................................ii List of Tables ...............................................................................................................................
    [Show full text]
  • Monoclonal Antibodies Against Cd30 Lacking In
    (19) TZZ_97688¥_T (11) EP 1 976 883 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07K 16/28 (2006.01) A61P 35/00 (2006.01) 03.10.2012 Bulletin 2012/40 A61P 37/00 (2006.01) (21) Application number: 07718000.8 (86) International application number: PCT/US2007/001451 (22) Date of filing: 17.01.2007 (87) International publication number: WO 2007/084672 (26.07.2007 Gazette 2007/30) (54) MONOCLONAL ANTIBODIES AGAINST CD30 LACKING IN FUCOSYL AND XYLOSYL RESIDUES MONOKLONALE ANTIKÖRPER GEGEN CD30 OHNE FUCOSYL- UND XYLOSYLRESTE ANTICORPS MONOCLONAUX ANTI-CD30 DEPOURVUS DE RESIDUS FUCOSYL ET XYLOSYL (84) Designated Contracting States: • WANG, Ming-Bo AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Canberra Australian Capital Territory 2617 (AU) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR (74) Representative: Tuxworth, Pamela M. Designated Extension States: J A Kemp RS 14 South Square Gray’s Inn (30) Priority: 17.01.2006 US 759298 P London WC1R 5JJ (GB) 07.04.2006 US 790373 P 11.04.2006 US 791178 P (56) References cited: 09.06.2006 US 812702 P WO-A-03/059282 US-A1- 2004 261 148 11.08.2006 US 837202 P 11.08.2006 US 836998 P • P. BORCHMANN ET AL.: "The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity (43) Date of publication of application: against malignant lymphoma." BLOOD, vol. 102, 08.10.2008 Bulletin 2008/41 no.
    [Show full text]
  • Regulatory Mechanisms of Apoptosis in Regularly Dividing Cells
    Cell Health and Cytoskeleton Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Regulatory mechanisms of apoptosis in regularly dividing cells Ribal S Darwish Abstract: The balance between cell survival and death is essential for normal development and Department of Anesthesiology, homeostasis of organisms. Apoptosis is a distinct type of cell death with ultrastructural features Division of Critical Care Medicine, that are consistent with an active, inherently controlled process. Abnormalities and dysregulation University of Maryland Medical of apoptosis contribute to the pathophysiology of multiple disease processes. Apoptosis is strictly Center, Baltimore, Maryland, USA regulated by several positive and negative feedback mechanisms that regulate cell death and determine the final outcome after cell exposure to apoptotic stimuli. Mitochondria and caspases are central components of the regulatory mechanisms of apoptosis. Recently, noncaspase pathways of apoptosis have been explored through the studies of apoptosis-inducing factor and endonu- clease G. Multiple difficulties in the apoptosis research relate to apoptosis detection and imaging. For personal use only. This article reviews current understanding of the regulatory mechanisms of apoptosis. Keywords: caspases, apoptosis-inducing factor, apoptosis inhibitory proteins, cytochrome c, mitochondria Introduction Apoptosis is a distinct type of cell death with ultrastructural features that are con- sistent with an active, inherently controlled process, and it is a part of the necrobio- sis, a process that is essential in maintaining tissue homeostasis. The concept that cells must be lost from the normal tissues to balance their mitotic activity was first proposed by the German anatomist Ludwig Graper,1 who proposed that chromolysis must exist in the cells that will be eliminated.
    [Show full text]
  • US 2017/0020926 A1 Mata-Fink Et Al
    US 20170020926A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0020926 A1 Mata-Fink et al. (43) Pub. Date: Jan. 26, 2017 (54) METHODS AND COMPOSITIONS FOR 62/006,825, filed on Jun. 2, 2014, provisional appli MMUNOMODULATION cation No. 62/006,829, filed on Jun. 2, 2014, provi sional application No. 62/006,832, filed on Jun. 2, (71) Applicant: RUBIUS THERAPEUTICS, INC., 2014, provisional application No. 61/991.319, filed Cambridge, MA (US) on May 9, 2014, provisional application No. 61/973, 764, filed on Apr. 1, 2014, provisional application No. (72) Inventors: Jordi Mata-Fink, Somerville, MA 61/973,763, filed on Apr. 1, 2014. (US); John Round, Cambridge, MA (US); Noubar B. Afeyan, Lexington, (30) Foreign Application Priority Data MA (US); Avak Kahvejian, Arlington, MA (US) Nov. 12, 2014 (US) ................. PCT/US2O14/0653O4 (21) Appl. No.: 15/301,046 Publication Classification (22) PCT Fed: Mar. 13, 2015 (51) Int. Cl. A6II 35/28 (2006.01) (86) PCT No.: PCT/US2O15/02O614 CI2N 5/078 (2006.01) (52) U.S. Cl. S 371 (c)(1), CPC ............. A61K 35/28 (2013.01); C12N5/0641 (2) Date: Sep. 30, 2016 (2013.01): CI2N 5/0644 (2013.01); A61 K Related U.S. Application Data 2035/122 (2013.01) (60) Provisional application No. 62/059,100, filed on Oct. (57) ABSTRACT 2, 2014, provisional application No. 62/025,367, filed on Jul. 16, 2014, provisional application No. 62/006, Provided are cells containing exogenous antigen and uses 828, filed on Jun. 2, 2014, provisional application No.
    [Show full text]
  • Modulators of the Function of FAS Receptors and Other Proteins
    (19) *EP002042509A1* (11) EP 2 042 509 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 01.04.2009 Bulletin 2009/14 C07H 21/04 (2006.01) C12N 15/63 (2006.01) C12N 15/85 (2006.01) C12N 15/86 (2006.01) (2006.01) (2006.01) (21) Application number: 08018971.5 C07K 14/00 A61K 39/395 (22) Date of filing: 14.06.1996 (84) Designated Contracting States: (72) Inventors: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC • Wallach, David NL PT SE 76406 Rehovot (IL) Designated Extension States: • Boldin, Mark AL LT LV SI 76000 Rehovot (IL) • Goncharov, Tanya (30) Priority: 16.07.1995 IL 11461595 76000 Rehovot (IL) 17.08.1995 IL 11498695 • Goltsev, Yury 14.09.1995 IL 11531995 76000 Rehovot (IL) 27.12.1995 IL 11658895 16.04.1996 IL 11793296 (74) Representative: Vossius & Partner Siebertstraße 4 (62) Document number(s) of the earlier application(s) in 81675 München (DE) accordance with Art. 76 EPC: 96919472.9 / 0 914 325 Remarks: This application was filed on 30-10-2008 as a (71) Applicant: YEDA RESEARCH AND divisional application to the application mentioned DEVELOPMENT COMPANY, LTD. under INID code 62. 76 100 Rehovot (IL) (54) Modulators of the function of FAS receptors and other proteins (57) The present invention provides proteins capable ceptor. In addition, peptide inhibitors which interfere with of modulating or mediating the FAS receptor ligand or the proteolytic activity of MORT-1-binding proteins hav- TNF effect on cells carrying FAS receptor or p55 receptor ing proteolytic activity are provided as well as a method by binding or interacting with MORT-1 protein, which in of designing them.
    [Show full text]
  • 1 Women for Sobriety Combined Bibliographies
    Women for Sobriety Combined Bibliographies (June 2016) Compiled by Rita A. Chaney, MS Women for Sobriety Professional Bibliography Abbott, A. A., & Olson, M. (1994). A feminist approach to substance abuse treatment and service delivery. Women’s Health & Social Work, 67-83. Angove, R., & Fothergill, A. (2003, April). Women and alcohol: Misrepresented and misunderstood. Journal of Psychiatric & Mental Health Nursing, 10(2), 213-219. doi: 10.1046/j.1365-2850.2003.00587.x. Atkins, Jr., J. R, & Hawdon, J. E. (2007). Religiosity and participation in mutual-aid support groups for addiction. Journal of Substance Abuse Treatment, 33(3), 321-331. Berenson, D. (1992). Powerlessness—Liberating or enslaving? Responding to the feminist critique of the Twelve Steps. Journal of Feminist Family Therapy, 3(3), 67-84. Bogart, C. J., & Pearce, C. E. (2003). “13th-Stepping:” Why Alcoholics Anonymous is not always a safe place for women. Journal of Addictions Nursing, 14, 43-47. Bond, L. M., & Csordas, T. J. (2014). The paradox of powerlessness. Alcoholism Treatment Quarterly, 32(2-3), 141-156. Chaney, R., & White, W. L. (1992). Metaphors of transformation: Feminine and masculine. Bloomington, IL: Lighthouse Training Institute. Fenner, R.M., & Gifford, M.H. (2012). Women for Sobriety: 35 years of challenges, changes, and continuity. Journal of Groups in Addiction and Recovery, 7(2-4), 142-170. Fenner, R.M., & Gifford, M.H. (2015). Women for Sobriety: An alternative recovery choice. Counselor, 16(4), 18-21. Hafner, S. (1992). Nice girls don’t drink: Stories of recovery. New York, NY: Bergin & Garvey. [An interview of Kirkpatrick]. Hall, M. J., & Tidwell, W.
    [Show full text]
  • C07k - 2021.08
    CPC - C07K - 2021.08 C07K PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D 519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G 69/00; macromolecular products derived from proteins C08H 1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N 15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N 33/00) Relationships with other classification places An amino acid per se is classified in C07D while peptides (starting from dipeptides) are classified in C07K. Subclass C07K is a function oriented entry for the compounds themselves and does not cover the application or use of the compounds under the subclass definition. For classifying such information other entries exist, for example: preservation of bodies of humans or animals or plants or parts thereof; Biocides, e.g. as disinfectants, as pesticides, as herbicides; pest repellants or attractants; plant growth regulators are classified in A01N. Preparations for medical, dental, or toilet purposes are classified in A61K. Amino acids or derivatives thereof are classified in C07C or C07D.
    [Show full text]
  • 2020 Census National Redistricting Data Summary File 2020 Census of Population and Housing
    2020 Census National Redistricting Data Summary File 2020 Census of Population and Housing Technical Documentation Issued February 2021 SFNRD/20-02 Additional For additional information concerning the Census Redistricting Data Information Program and the Public Law 94-171 Redistricting Data, contact the Census Redistricting and Voting Rights Data Office, U.S. Census Bureau, Washington, DC, 20233 or phone 1-301-763-4039. For additional information concerning data disc software issues, contact the COTS Integration Branch, Applications Development and Services Division, Census Bureau, Washington, DC, 20233 or phone 1-301-763-8004. For additional information concerning data downloads, contact the Dissemination Outreach Branch of the Census Bureau at <[email protected]> or the Call Center at 1-800-823-8282. 2020 Census National Redistricting Data Summary File Issued February 2021 2020 Census of Population and Housing SFNRD/20-01 U.S. Department of Commerce Wynn Coggins, Acting Agency Head U.S. CENSUS BUREAU Dr. Ron Jarmin, Acting Director Suggested Citation FILE: 2020 Census National Redistricting Data Summary File Prepared by the U.S. Census Bureau, 2021 TECHNICAL DOCUMENTATION: 2020 Census National Redistricting Data (Public Law 94-171) Technical Documentation Prepared by the U.S. Census Bureau, 2021 U.S. CENSUS BUREAU Dr. Ron Jarmin, Acting Director Dr. Ron Jarmin, Deputy Director and Chief Operating Officer Albert E. Fontenot, Jr., Associate Director for Decennial Census Programs Deborah M. Stempowski, Assistant Director for Decennial Census Programs Operations and Schedule Management Michael T. Thieme, Assistant Director for Decennial Census Programs Systems and Contracts Jennifer W. Reichert, Chief, Decennial Census Management Division Chapter 1.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,799,902 B2 Browning Et A1
    USOO7799902B2 (12) United States Patent (10) Patent No.: US 7,799,902 B2 Browning et a1. (45) Date of Patent: Sep. 21, 2010 (M)IEEDHORCOUHJMLKENBAND 2mmmww4Ai umm @m?an COMPOSITIONS THEREOF 2004/0198635 A1 10/2004 Browning et al. 2005/0037003 A1 2/2005 Browning et al. (75) Inventors: Jeffrey L. Browning, Cambridge, MA 2005/0281811 A1 12/2005 Browning et al. (US); Veronique Bailly, Boxborough, 2006/0104971 A1 5/2006 Garber et a1. MA (US); Ellen Garber, Cambridge, 2006/0134102 A1 6/2006 LePage et a1. MA (US) 2006/0222644 A1 10/2006 Garber et a1. 2006/0280722 A1 12/2006 Browning et al. (73) Assignee: Biogen Idec MA Inc., Cambridge, MA 2007/0154476 A1 7/2007 Browning et al. (Us) (*) Notice: Subject to any disclaimer, the term of this FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 U.S.C. 154(b) by 420 days. EP 0509553 B1 10/1992 EP 0519596 B1 12/1992 (21) App1.No.: 11/524,786 WO WO-91/09967 A1 7/1991 WO WO-92/00329 A1 1/1992 (22) Filed: Sep. 21, 2006 WO WO-94/04679 A1 3/1994 WO WO-94/ 13808 A2 6/ 1994 (65) Prior Publication Data WO WO-94/ 13808 A3 6/ 1994 US 2007/0154476 A1 Jul. 5, 2007 WO WO-94/20625 A1 9/1994 WO WO-96/22788 A1 8/1996 Related US. Application Data WO WO-97/03687 A1 2/1997 (63) Continuation of application No. PCT/US2005/ WO WO-99/38525 A1 8/1999 009967, ?led on Mar. 23, 2005.
    [Show full text]
  • Emerging Roles of Lymphatic Endothelium in Regulating Adaptive Immunity
    Emerging roles of lymphatic endothelium in regulating adaptive immunity Catherine M. Card, … , Shann S. Yu, Melody A. Swartz J Clin Invest. 2014;124(3):943-952. https://doi.org/10.1172/JCI73316. Review Series Emerging research on the roles of stromal cells in modulating adaptive immune responses has included a new focus on lymphatic endothelial cells (LECs). LECs are presumably the first cells that come into direct contact with peripheral antigens, cytokines, danger signals, and immune cells travelling from peripheral tissues to lymph nodes. LECs can modulate dendritic cell function, present antigens to T cells on MHC class I and MHC class II molecules, and express immunomodulatory cytokines and receptors, which suggests that their roles in adaptive immunity are far more extensive than previously realized. This Review summarizes the emergent evidence that LECs are important in maintaining peripheral tolerance, limiting and resolving effector T cell responses, and modulating leukocyte function. Find the latest version: https://jci.me/73316/pdf Review series Emerging roles of lymphatic endothelium in regulating adaptive immunity Catherine M. Card, Shann S. Yu, and Melody A. Swartz Institute of Bioengineering and Swiss Institute for Experimental Cancer Research, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland. Emerging research on the roles of stromal cells in modulating adaptive immune responses has included a new focus on lymphatic endothelial cells (LECs). LECs are presumably the first cells that come into direct contact with peripheral antigens, cytokines, danger signals, and immune cells travelling from peripheral tissues to lymph nodes. LECs can modulate dendritic cell function, present antigens to T cells on MHC class I and MHC class II molecules, and express immunomodulatory cytokines and receptors, which suggests that their roles in adaptive immunity are far more extensive than previously realized.
    [Show full text]
  • Modulation of NK Cell Function with Agonistic Α-CD137 Antibodies
    Modulation of NK Cell Function with Agonistic -CD137 Antibodies during MCMV Infection Dahn Hahm A thesis submitted to the Faculty of Graduate and Postdoctoral Studies in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE in Microbiology and Immunology Department of Biochemistry, Microbiology and Immunology Faculty of Medicine University of Ottawa © Dahn Hahm, Ottawa, Canada, 2017 ABSTRACT The Tumor Necrosis Factor Receptor Superfamily (TNFR) is responsible in regulating a myriad of physiological function including the regulation of the immune system. Among the members include CD137 (4-1BB), an inducible costimulatory receptor known for its potent activation, proliferation, and survival effects on T cells. Stimulation of NK cells with agonistic -CD137 antibodies are known to increase IFN- production and proliferation in NK cells as well as increase efficacy of anti-tumor responses. However, NK cell death has also been seen in certain circumstances, although the mechanism remains to be determined. In vitro stimulation of NK cells revealed that -CD137 induced NK cell death occurs through both TNFR1 and TNFR2, although the action of TNF- and TNF- remain uncertain. Death was independent of other cytotoxic mechanisms such as granzyme/perforin, Fas-Fas ligand, and TRAIL. During MCMV infection, -CD137 induces NK cell death during the early phase of infection reducing viral resistance. This causes increased viral proliferation which drives NK cell proliferation, likely through Ly49H-m157 interactions, to high levels by day 4 of infection. The use of -CD137 as a tumor therapeutic is promising with several applications undergoing clinical trials. However, my results raise concern of other effects including the depletion of NK cells.
    [Show full text]
  • Fax: 800-863-7041 E-Mail: Info
    Page Part# Description Page Part# Description BUNN CECILWARE 160 B22300.750 FLOW CNTRL W/SCREEN .750 167 CD61A CAP, DISPENSE 163 B23721.0000 SCREEN, STRAINER 167 CD63A CHAMBER, WHIPPER MIXING 159 B23799.1 CORD, POWER 6’ 12/3 50-20P 167 CD64A BLADE, WHIPPER 162 B24331 O-RING 167 CD65A CHAMBER, MOUNT WITH SEAL 162 B24733 O-RING CAPPUCCINO 168 CD66A PILLAR MOUNTING PLATE 162 B24733.1 O-RING 168 CD67A MIXING BOWL, SOCKET 163 B25137 RUBBER FOOT .250, 1/4-20 STUD 168 CD68A HOPPER W/BASE 4 LB 163 B25137.1 RUBBER FOOT .480, 1/4-20 STUD 168 CD75A MOTOR, WHIPPER 163 B25137.2 RUBBER FOOT .480, 8/32 STUD 167 CE76A BULB, FLUORESCENT F8T5CW 164 B25732 STEAM COLLECTOR 167 CE82A BULB, FLUORESCENT 18 WT 158 B25733 CHAMBER, MIXING 168 D017A FAUCET, URN CHROME/BLK HDL 158 B25734 CHAMBER, WHIPPING 168 K355Q PROBE, WATER LEVEL 159 B25736 DISPENSE TIP 168 K402Q PROBE, WATER LEVEL 161 B25902 FROTHER 168 K695Q SENSOR, DUAL LIQUID LEVEL 159 B25903 ELBOW, EJECTOR 167 L042A BULB, FLOURESENT 9 WT 163 B25948 RELAY, 120V 169 L266L THERMOASTAT 165 B26116 VALVE, BUNN DISPENSE 169 L299A SWITCH, TOGGLE 166 B26135.1 VALVE, INLET (120V) 168 L396A STARTER, FLUORESCENT FS5 158 B26239 BULB, FLOURESCENT F8T5CW 167 L398A CNTRL BRD LEVEL 163 B26359 RECEPTACLE, WHIPPER CHAMBER 168 L455A SWITCH, DISPENSE 161 B26504 HINGE, ADJUSTABLE 169 L462A VALVE, INLET CECILWARE 162 B26528 LEG, ADJUSTABLE 4” 3/8 x 16 169 L467A VALVE, DUMP 162 B26528.1 LEG, ADJUSTABLE 1/4 - 20 169 L499A SWITCH, FLOAT 160 B26685 FAUCET, TEA FOR GPR 169 L561A VALVE, DISPENSE 165 B27370 VALVE, DISPENSE 168 L643A
    [Show full text]